Health Secretary Robert F. Kennedy Jr. said at a Senate hearing that he played no role in the FDA's decision not to approve Replimune's drug for advanced skin cancer, placing the decision with FDA Commissioner Dr. Marty Makary. The article is a factual clarification around regulatory responsibility rather than a direct update on the drug's prospects. Market impact should be limited unless it signals broader changes in FDA review dynamics.
Health Secretary Robert F. Kennedy Jr. said at a Senate hearing that he played no role in the FDA's decision not to approve Replimune's drug for advanced skin cancer, placing the decision with FDA Commissioner Dr. Marty Makary. The article is a factual clarification around regulatory responsibility rather than a direct update on the drug's prospects. Market impact should be limited unless it signals broader changes in FDA review dynamics.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
neutral
Sentiment Score
-0.10
Ticker Sentiment
